The federal government notified drug makers Lilly, Novo Nordisk, and Sanofi in court papers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion, in connection with AstraZeneca’s contract pharmacy lawsuit. It said the withdrawal does not
…
Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports. Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic
…
President Biden last Friday nominated career civil servant Christi Grimm to serve as Inspector General of the U.S. Health and Human Services Department (HHS).
The HHS Office of Inspector General (OIG) has issued numerous reports on the 340B program on
…
HHS Withdraws 340B Contract Pharmacy Advisory Opinion, Says May 17 Demand Letters Are Unaffected
The U.S. Health and Human Services Department (HHS) yesterday withdrew its December 2020 legal advisory opinion (AO) that the 340B statute unambiguously requires drug manufacturers to
…
Groups representing 340B covered entities are emphasizing the positives in what they say was a federal judge’s otherwise disappointing opinion Wednesday on whether drug makers must offer 340B ceiling prices when covered entities use contract pharmacies.
The groups’ message is,
…
The U.S. Supreme Court ruled 7-2 this morning that Texas and a dozen other Republican-led states lacked standing to challenge the constitutionality of the Affordable Care Act.
In addition to expanding health insurance to 21 million Americans, the ACA included
…
A congressman from New York asked U.S. Health and Human Services Xavier Becerra during a hearing yesterday if he will use his existing authority to protect hospitals from losing eligibility for 340B drug discounts due to changes in patient mix
…
The American Hospital Association (AHA) told pharmacy benefit manager Express Scripts (ESI) this week its new 340B claims identification requirement for covered entities and their contract pharmacies “is a major overreach” and should be withdrawn immediately.
An ESI spokesperson was
…
SPONSORED CONTENT by Kristin Fox-Smith and William Wood, Visante
Those of us actively engaged in the 340B Program are well aware of the scores of issues faced by participating hospitals and it’s not surprising since they account for an exceptionally large percentage of all HRSA audits. But, what about other types
…*Sign up for news summaries and alerts from 340B Report
